American Oriental Bioengineering Introduces Wujia Rongxue Oral Liquid

NEW YORK, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving healthcare through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced the commercial launch of AOBO Wujia Rongxue Oral Liquid, ("AWRO Liquid"), an OTC herbal supplement aimed at boosting energy and health, especially for middle aged and elderly individuals, by strengthening their kidney function, which is believed to play a critical role in health according to the doctrines of traditional Chinese medicine.  

Mr. Tony Liu, Chairman and CEO of AOBO, commented, "As the disposable income increases in China, the demand for health supplements has also risen rapidly.  In China, individuals not only purchase these supplements for themselves but also as gifts for others.  In fact, gift purchases contribute significantly to the strong performance of the health supplements market. Although not so popular in the USA, this gift purchase behavior pattern in the health supplement market is common place in China. We believe the addition of AWRO Liquid will complement our existing product offerings as well as contribute to the growth momentum of our future OTC product sales."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter products.  

Forward-Looking Statements

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.  The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:
ICR, LLC
Christine Duan or Ashley Ammon
646-277-1200

SOURCE American Oriental Bioengineering, Inc.

Copyright 2010 PR Newswire